Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company
Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011
Human Vaccines & Immunotherapeutics 2013; 9:1598 – 1607; PMID: 23846304; https://dx.doi.org/10.4161/hv.25598
Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice
Hum Vaccin Immunother. 2013 Sep 17;9(10).